Skip to main content

Table 2 Demographic and baseline characteristics for adherence by supervision

From: Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

 

Adherence by supervision (%)

Overall (N = 6917)

 ≤ 50 (N = 2790)

 ≥ 90 (N = 4127)

Sex

 Female

1036 (37.1%)

1493 (36.2%)

2529 (36.6%)

 Male

1754 (62.9%)

2630 (63.8%)

4384 (63.4%)

Age (years)

 Median [IQR]

23.0 (11.0–37.9)

17.1 (11.0–29.0)

19.0 (11.0–32.0)

  < 5

191 (6.8%)

261 (6.3%)

452 (6.5%)

 5–15

726 (26.0%)

1409 (34.2%)

2135 (30.9%)

  > = 15

1872 (67.1%)

2453 (59.5%)

4325 (62.6%)

Relapse periodicity

 Low periodicity

1580 (56.6%)

1489 (36.1%)

3069 (44.4%)

 High periodicity

1210 (43.4%)

2635 (63.9%)

3845 (55.6%)

Geographical region

 Africa

207 (7.4%)

465 (11.3%)

672 (9.7%)

 Americas

722 (25.9%)

616 (14.9%)

1338 (19.4%)

 Asia–Pacific

1861 (66.7%)

3043 (73.8%)

4904 (70.9%)

Transmission intensity of study site

 Low

261 (9.4%)

1526 (37.0%)

1787 (25.8%)

 Moderate

1239 (44.4%)

1427 (34.6%)

2666 (38.6%)

 High

1290 (46.2%)

1171 (28.4%)

2461 (35.6%)

Blood-stage drug elimination half-life

 Rapid, < 1 day

50 (1.8%)

0 (0.0%)

50 (0.7%)

 Intermediate, 1–7 days

217 (7.8%)

31 (0.8%)

248 (3.6%)

 Slow, > 7 days

2523 (90.4%)

4096 (99.2%)

6619 (95.7%)

Primaquine regimen duration

  < 14 days

1136 (40.7%)

1967 (47.7%)

3103 (44.9%)

 14 days

1654 (59.3%)

2160 (52.3%)

3814 (55.1%)

Start day of primaquine

 Day 0/1

2025 (72.6%)

3990 (96.7%)

6015 (87.0%)

 Day 2/3

765 (27.4%)

137 (3.3%)

902 (13.0%)

Planned primaquine total dose

 Very low dose

78 (2.8%)

208 (5.0%)

286 (4.1%)

 Low dose

2641 (94.7%)

1708 (41.4%)

4349 (62.9%)

 High dose

71 (2.5%)

2206 (53.5%)

2277 (32.9%)

Malnutrition

 Yes

19 (18.1%)

64 (24.6%)

83 (22.7%)

 No

86 (81.9%)

196 (75.4%)

282 (77.3%)

Fever at baseline, temperature > 37.5 °C

 Yes

1222 (57.9%)

1615 (45.0%)

2837 (49.8%)

 No

889 (42.1%)

1975 (55.0%)

2864 (50.2%)

Weight (kg)

57.0 (45.0–68.0)

47.0 (27.0–57.6)

50.0 (30.8–61.2)

Haemoglobin (g/dL)

12.7 (11.2–14.0)

12.7 (11.5–14.0)

12.7 (11.4–14.0)

Parasitaemia, parasites per μL

2520.0 (960.0–5802.0)

3189.8 (870.4–8923.0)

2938.5 (900.0–7500.0)

  1. Data are presented as median (IQR) for continuous measures, and n (%) for categorical measures
  2. IQR – Interquartile range; there were no patients with adherence by supervision between > 50- < 90%
  3. Data were missing for the following variables: sex (4 patients in the ≥ 90% group), age (4 patients in ≥ 90% group and 1 patient in the ≤ 50% group), relapse periodicity, geographical region, and transmission intensity of study site (3 patients in the ≥ 90% group), planned total dose of primaquine (5 patients in the ≥ 90% group), malnutrition status – calculated for children aged < 5 years of age (86 patients in ≤ 50% group and 1 patient in the ≥ 90% group), fever (679 patients in ≤ 50% and 537 patients in the ≥ 90% group), baseline parasitaemia (122 patients in ≥ 90% group and 449 patient in the ≤ 50% group), baseline haemoglobin (518 patients in ≥ 90% group and 828 patient in the ≤ 50% group), weight (65 patients in ≥ 90% group and 807 patient in the ≤ 50% group)
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us